S A PLOTKIN - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

S A PLOTKIN

Showing results (151-160 of 153) with videos related to

Pageof 16

Sort By:

You have reached the last page of results.This site can display upto 153 results.

Vaccine|September 1, 1991

Oka/Merck varicella vaccine in healthy children: final report of a 2-year efficacy study and 7-year follow-up studiesB J Kuter, R E Weibel, H A Guess, et al.

The Journal of Infectious Diseases|August 7, 1999

A canarypox vector expressing cytomegalovirus (CMV) glycoprotein B primes for antibody responses to a live attenuated CMV vaccine (Towne)S P Adler, S A Plotkin, E Gonczol, et al.

The Journal of Infectious Diseases|September 1, 1996

The development of multivalent bovine rotavirus (strain WC3) reassortant vaccine for infantsH F Clark, P A Offit, R W Ellis, et al.

Pageof 16

Search research articles

Showing results (151-160 of 153) with videos related to

Sort By:

Pageof 16

You have reached the last page of results.This site can display upto 153 results.

Vaccine|September 1, 1991

Oka/Merck varicella vaccine in healthy children: final report of a 2-year efficacy study and 7-year follow-up studiesB J Kuter, R E Weibel, H A Guess, et al.

The Journal of Infectious Diseases|August 7, 1999

A canarypox vector expressing cytomegalovirus (CMV) glycoprotein B primes for antibody responses to a live attenuated CMV vaccine (Towne)S P Adler, S A Plotkin, E Gonczol, et al.

The Journal of Infectious Diseases|September 1, 1996

The development of multivalent bovine rotavirus (strain WC3) reassortant vaccine for infantsH F Clark, P A Offit, R W Ellis, et al.

Pageof 16